HeMemics Announces Election of Larry Simpson to Its Board of Directors
Election of Larry Simpson to HeMemics Board of Directors
Rockville, MD, February 15, 2014 --(PR.com)-- HeMemics Biotechnologies, Inc. (http://www.hememics.com), announced today the election of Larry Simpson as a member of its Board of Directors. The company’s Board of Directors now consists of five members.
Larry has over 25 years as a business leader having served as an entrepreneur, executive, investor, and Board member. He has held leadership roles of CEO, President & COO, and Vice President positions for Sales and Business Development, Operations, and Product Development. His market experiences include software, health, eBusiness, secure communications, and professional services industries that have spanned the commercial, government, and international sectors.
As an executive, Larry has led emerging technology companies with top level personnel from start-up as a founder to exits, restart of VC backed company, turn-around of a division of a public owned company, participated in IPO, secondary offering, merger & acquisitions, and venture raises. He has served as an executive and on the Board of Directors of private, public, and nonprofit organizations.
About HeMemics Biotechnologies, Inc.
HeMemics is a development and manufacturing company that is privately held. Our core competence is applying HeMeDri™, the HeMemics proprietary desiccation technology platform to solve preservation, storage and shipping problems that involve dehydrating and rehydrating proteins, cells and tissues. This platform can be applied to preserving blood and blood components, a wide variety of other cells, and selected tissues with or without desiccation. HeMemics has used this platform to preserve and dehydrate/rehydrate perishable biologics (proteins, cells, tissues, etc.) and has developed processes to extend the shelf life while transporting cells for medical and non-medical applications. The company has demonstrated capabilities to deliver commercial reagents for use in blood banks, hospitals and clinics and for transporting mammalian cells at ambient temperature for use in pharmaceutical or academic research labs. HeMemics has recently demonstrated in vitro, the efficacy of using its buffer for preserving red blood cells for transfusion and in vivo for extending the shelf life and improving the safety of platelets for transfusion. Our technologies and processes can fulfill a number of market requirements for stabilized biologic products for use in research, diagnostic and therapeutic applications.
Contact:
Bruce Campbell--President
bcampbell@hememics.com
Larry has over 25 years as a business leader having served as an entrepreneur, executive, investor, and Board member. He has held leadership roles of CEO, President & COO, and Vice President positions for Sales and Business Development, Operations, and Product Development. His market experiences include software, health, eBusiness, secure communications, and professional services industries that have spanned the commercial, government, and international sectors.
As an executive, Larry has led emerging technology companies with top level personnel from start-up as a founder to exits, restart of VC backed company, turn-around of a division of a public owned company, participated in IPO, secondary offering, merger & acquisitions, and venture raises. He has served as an executive and on the Board of Directors of private, public, and nonprofit organizations.
About HeMemics Biotechnologies, Inc.
HeMemics is a development and manufacturing company that is privately held. Our core competence is applying HeMeDri™, the HeMemics proprietary desiccation technology platform to solve preservation, storage and shipping problems that involve dehydrating and rehydrating proteins, cells and tissues. This platform can be applied to preserving blood and blood components, a wide variety of other cells, and selected tissues with or without desiccation. HeMemics has used this platform to preserve and dehydrate/rehydrate perishable biologics (proteins, cells, tissues, etc.) and has developed processes to extend the shelf life while transporting cells for medical and non-medical applications. The company has demonstrated capabilities to deliver commercial reagents for use in blood banks, hospitals and clinics and for transporting mammalian cells at ambient temperature for use in pharmaceutical or academic research labs. HeMemics has recently demonstrated in vitro, the efficacy of using its buffer for preserving red blood cells for transfusion and in vivo for extending the shelf life and improving the safety of platelets for transfusion. Our technologies and processes can fulfill a number of market requirements for stabilized biologic products for use in research, diagnostic and therapeutic applications.
Contact:
Bruce Campbell--President
bcampbell@hememics.com
Contact
HeMemics Biotech
David Ho
301-560-0415
www.hememics.com
David Ho
301-560-0415
www.hememics.com
Contact
Categories